The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Astron Pulsar Stents
The purpose of this study is to evaluate the Astron and Astron Pulsar stents in patients with blockages in the arteries of the abdomen and legs.
Sponsor: Biotronk, Inc Principal Investigator: Janet Strain, MD Co-Investigators: Daniel Char, MD, Joshua Bernheim, MD
For more information, please call 201-447-8453.
Carotid Stenting for High Surgical Risk Patients; Evaluating Outcomes Through the Collection of Clinical Evidence
The purpose of this study is to evaluate clinical outcomes of patients after they receive a stent in their carotid artery.
Sponsor: Abbott Vascular Principal Investigator: Joshua Bernheim, MD Co-Investigators: Daniel Char, MD, Joshua Bernheim, MD
A Phase III, Multi-center, Double-Blind, Randomized, Placebo Controlled Study Evaluating the Effect of Treatment with Dalcetrapib 600 mg on Atherosclerotic Disease as Measured by 1. Coronary Intravascular Ultrasound (IVUS) and Quantitative Coronary Angiography 2. Carotid B-Mode Ultrasound intima media thickness (IMT) and Total plaque volume in Subjects Undergoing Coronary Angiography who have Coronary Artery Disease.
The purpose of this study is to evaluate the effect of dalcetrapib on the amount of plaque in the arteries of the heart and neck. Patients have to return for a repeat angiogram after 2 years on study drug.
Sponsor: Hoffman La Roche, Inc. Principal Investigator: Janet Strain, MD Co-Investigators: Arvind Agarwal, MD, Michael Kesselbrenner, MD, Navin Budhwani, MD, Dennis Reison, MD.
A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm
The purpose of this study is to evaluate if the new Endeavor Resolute stent is safe and how effective the drug-eluting stent is in reducing the re-narrowing in coronary arteries over time.
Sponsor: Medtronic Vascular, Inc. Principal Investigator: Janet Strain, MD Co-Investigators: Arvind Agarwal, MD; Navin Budhwani, MD; Michael Kesselbrenner, MD; Dennis Reison, MD; Elliott Lichtstein, MD
A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.
The purpose of this study is to determine the benefit of continuing dual antiplatelet therapy for longer than 12 months after receiving a stent. If eligible, 1 year after stent placement, patients are randomized to Plavix or placebo, or Effient or placebo.
Sponsor: Harvard Clinical Research Institute (HCRI) Principal Investigator: Arvind Agarwal, MD Co-Investigators: Janet Strain, MD, Dennis Reison, MD, Navin Budhwani, MD, Elliott Lichtstein, MD, Michael Kesselbrenner, MD, Robert Saporito, MD, Joseph Wiedermann, MD.
Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study
The purpose of this Study is to evaluate the continued safety and effectiveness of the XIENCE V™ Everolimus Eluting Coronary Stent System (the XIENCE V EECSS) recently approved for use by the Food and Drug Administration (FDA) for the treatment of narrowed coronary arteries (blood vessels in the heart) in a group of real-world patients.
Sponsor: Abbott Cardiovascular Systems, Inc. Principal Investigator: Arvind Agarwal, MD Sub-Investigators: Janet Strain, MD; Dennis Reison, MD; Navin Budhwani, MD; Steven Kernis, MD; Giovani Camponile, MD; Michael Kesselbrenner, MD; Elliott Lichtstein, MD